NewLimit, a startup dedicated to longevity research, has announced a significant funding milestone of $435 million.
This funding will be directed towards launching the company's first clinical trial, which will focus on a liver medicine.
The substantial investment highlights the growing interest and potential in the field of longevity and medical advancements.